Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
Authors
Keywords
Epidermal Growth Factor Receptor, Erlotinib, HDAC Inhibition, Epidermal Growth Factor Receptor Activation, Epidermal Growth Factor Receptor TKIs
Journal
Targeted Oncology
Volume 11, Issue 1, Pages 29-40
Publisher
Springer Nature
Online
2015-06-03
DOI
10.1007/s11523-015-0372-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors
- (2014) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Erlotinib: early clinical development in brain cancer
- (2014) Raffaele Addeo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
- (2014) Bertrand Coiffier et al. Journal of Hematology & Oncology
- Histone deacetylase inhibitors
- (2013) Marije Slingerland et al. ANTI-CANCER DRUGS
- Targeting a Glioblastoma Cancer Stem-Cell Population Defined by EGF Receptor Variant III
- (2013) D. R. Emlet et al. CANCER RESEARCH
- Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
- (2013) J. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110
- (2013) A. Schulte et al. NEURO-ONCOLOGY
- HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade
- (2013) Y J Kim et al. ONCOGENE
- Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
- (2013) David A. Nathanson et al. SCIENCE
- Glioblastoma Stem-like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration
- (2012) A. Schulte et al. CLINICAL CANCER RESEARCH
- EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms
- (2012) C A Del Vecchio et al. ONCOGENE
- The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models
- (2011) M. J. LaBonte et al. CANCER RESEARCH
- A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target
- (2011) Alexander Schulte et al. GLIA
- Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib--A Phase II Trial
- (2011) M. E. Hegi et al. MOLECULAR CANCER THERAPEUTICS
- The neurobiology of gliomas: from cell biology to the development of therapeutic approaches
- (2011) Manfred Westphal et al. NATURE REVIEWS NEUROSCIENCE
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
- (2011) Fabio M. Iwamoto et al. NEURO-ONCOLOGY
- HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
- (2011) Chia-Wei Chou et al. PLoS One
- Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors
- (2010) Hui Song et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
- (2010) Cheng-Jung Lai et al. CANCER RESEARCH
- Epidermal Growth Factor Receptor Expression Identifies Functionally and Molecularly Distinct Tumor-Initiating Cells in Human Glioblastoma Multiforme and Is Required for Gliomagenesis
- (2010) S. Mazzoleni et al. CANCER RESEARCH
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT
- (2010) Francesca Bruzzese et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
- (2010) Xiong Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
- (2009) J. H. Sampson et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search